NKMax America Announces Executive Advisory Board
SANTA ANA, Calif., Nov. 11, 2019 /PRNewswire/ -- NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that it has brought together an unparalleled group of thought leaders to provide expertise to the NKMax senior leadership team.
The Executive Advisory Board will cover key areas of strategic corporate development with a particular focus on industry partnerships and clinical advisement in oncology, autoimmune and neurodegenerative diseases. The board will provide external review and high-level advice to the NKMax team with regards to corporate strategy, product innovation, and pipeline development.
The Executive Advisory Board brings together the expertise of business development executives, scientists and clinicians who are highly regarded as thought-leaders in their field. Their accomplishments, forward thinking and unique insights will be invaluable in helping NKMax become a trusted leader in immune cell therapy.
“We are very pleased with the exceptional quality and proven leadership of our Executive Advisory Board,” commented Paul Song, MD, Vice Chairman and Chief Medical Officer of NKMax America. “With their deep experience in strategic partnerships, oncology, neurology and autoimmunity we are confident they will provide significant contributions to our future success.”
NKMax Executive Advisory Board members include:
About NKMax America
NKMax America, Inc is a biotech company specializing in both autologous and allogenic Natural Killer (NK) cell therapy utilizing proprietary cell expansion and cell activation technology. This therapeutic technology was developed as a complement to NKMax’s first-in-kind in vitro diagnostic test which measures NK cell activity using only one milliliter of whole blood.
For more information on the company, please visit www.nkmaxamerica.com
SOURCE NKMax America, Inc